Last reviewed · How we verify
taxane-based chemotherapy
taxane-based chemotherapy is a Taxane-based chemotherapy Small molecule drug developed by Jenny C. Chang, MD. It is currently in Phase 3 development for Metastatic breast cancer, Non-small cell lung cancer, Ovarian cancer. Also known as: Paclitaxel, Docetaxel, Abraxane, Ixabepilone.
Taxanes work by inhibiting microtubule dynamics, thereby preventing cell division and inducing apoptosis in rapidly dividing cancer cells.
Taxane-based chemotherapy, specifically docetaxel, is used to treat various types of cancer, including metastatic non-small cell lung cancer, triple negative breast cancer, and adenocarcinoma of the gastroesophageal junction. Docetaxel is a small molecule that works as a chemotherapeutic agent.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | taxane-based chemotherapy |
|---|---|
| Also known as | Paclitaxel, Docetaxel, Abraxane, Ixabepilone, non-investigational medicinal product (NIMP) |
| Sponsor | Jenny C. Chang, MD |
| Drug class | Taxane-based chemotherapy |
| Target | Microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Taxanes, such as paclitaxel and docetaxel, bind to tubulin and stabilize microtubules, preventing their disassembly and thereby inhibiting cell division. This leads to the accumulation of cells in the G2/M phase of the cell cycle and ultimately induces apoptosis in rapidly dividing cancer cells.
Approved indications
- Metastatic breast cancer
- Non-small cell lung cancer
- Ovarian cancer
Common side effects
- Neutropenia
- Anemia
- Fatigue
Key clinical trials
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (PHASE1, PHASE2)
- Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma (PHASE1, PHASE2)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (PHASE2, PHASE3)
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) (PHASE3)
- Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- taxane-based chemotherapy CI brief — competitive landscape report
- taxane-based chemotherapy updates RSS · CI watch RSS
- Jenny C. Chang, MD portfolio CI
Frequently asked questions about taxane-based chemotherapy
What is taxane-based chemotherapy?
How does taxane-based chemotherapy work?
What is taxane-based chemotherapy used for?
Who makes taxane-based chemotherapy?
Is taxane-based chemotherapy also known as anything else?
What drug class is taxane-based chemotherapy in?
What development phase is taxane-based chemotherapy in?
What are the side effects of taxane-based chemotherapy?
What does taxane-based chemotherapy target?
Related
- Drug class: All Taxane-based chemotherapy drugs
- Target: All drugs targeting Microtubules
- Manufacturer: Jenny C. Chang, MD — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic breast cancer
- Indication: Drugs for Non-small cell lung cancer
- Indication: Drugs for Ovarian cancer
- Also known as: Paclitaxel, Docetaxel, Abraxane, Ixabepilone, non-investigational medicinal product (NIMP)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing